Trial · NCT02036918
Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer
NCT02036918, Phase 1, Completed, Duke University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer. Trials, record NCT02036918. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02036918
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer
- NCT number
- NCT02036918
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 20 participants, actual
- Lead sponsor
- Duke University
- Conditions
- Prostate Cancer
- Interventions
- Sipuleucel-T, Lymph Node Biopsy
- First posted
- 2014-01-15
- Last updated
- 2020-03-31
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | anti-PA2024 immune response in lymph node-derived leukocytes | Lymph node biopsy, approximately 10 weeks | Proportion of patients with lymph node-derived leukocytes showing anti-PA2024 activity as measured by IFNγ ELISPOT |
| Primary | anti-PAP immune response in lymph node-derived leukocytes | Lymph node biopsy, approximately 10 weeks | Proportion of patients with lymph node-derived leukocytes showing anti-PAP activity as measured by IFNγ ELISPOT |
| Primary | anti-PA2024 immune response in PBMCs | Baseline | Proportion of patients with PBMC samples showing anti-PA2024 activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PAP immune response in PBMCs | Baseline | Proportion of patients with PBMC samples showing anti-PAP activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PA2024 immune response in PBMCs | Prior to sipuleucel-T infusion 2, approximately 6 weeks | Proportion of patients with PBMC samples showing anti-PA2024 activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PAP immune response in PBMCs | Prior to sipuleucel-T infusion 2, approximately 6 weeks | Proportion of patients with PBMC samples showing anti-PAP activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PA2024 immune response in PBMCs | Prior to sipuleucel-T infusion 3, approximately 8 weeks | Proportion of patients with PBMC samples showing anti-PA2024 activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PAP immune response in PBMCs | Prior to sipuleucel-T infusion 3, approximately 8 weeks | Proportion of patients with PBMC samples showing anti-PAP activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PA2024 immune response in PBMCs | 2 weeks after the last sipuleucel-T infusion | Proportion of patients with PBMC samples showing anti-PA2024 activity as measured by IFNγ ELISPOT at each time point |
| Primary | anti-PAP immune response in PBMCs | 2 weeks after the last sipuleucel-T infusion | Proportion of patients with PBMC samples showing anti-PAP activity as measured by IFNγ ELISPOT at each time point |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02036918
GET https://conductscience.org/api/trials/v1/NCT02036918/registered